Rhumbline Advisers Purchases 3,527 Shares of Evolent Health, Inc $EVH

Rhumbline Advisers raised its position in shares of Evolent Health, Inc (NYSE:EVH) by 2.1% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 169,918 shares of the technology company’s stock after acquiring an additional 3,527 shares during the period. Rhumbline Advisers owned approximately 0.14% of Evolent Health worth $1,609,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Banque Cantonale Vaudoise acquired a new stake in shares of Evolent Health in the first quarter valued at approximately $25,000. Strs Ohio acquired a new position in Evolent Health during the first quarter valued at approximately $47,000. US Bancorp DE raised its position in Evolent Health by 291.0% during the first quarter. US Bancorp DE now owns 5,153 shares of the technology company’s stock valued at $49,000 after purchasing an additional 3,835 shares in the last quarter. Signaturefd LLC raised its position in Evolent Health by 400.6% during the first quarter. Signaturefd LLC now owns 7,043 shares of the technology company’s stock valued at $67,000 after purchasing an additional 5,636 shares in the last quarter. Finally, GAMMA Investing LLC raised its position in Evolent Health by 5,036.4% during the first quarter. GAMMA Investing LLC now owns 9,451 shares of the technology company’s stock valued at $90,000 after purchasing an additional 9,267 shares in the last quarter.

Evolent Health Stock Performance

Shares of EVH opened at $8.75 on Friday. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 0.72. The stock has a market capitalization of $1.03 billion, a P/E ratio of -5.43 and a beta of 0.73. The firm’s fifty day simple moving average is $9.59 and its two-hundred day simple moving average is $9.49. Evolent Health, Inc has a 12 month low of $7.06 and a 12 month high of $31.67.

Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Thursday, August 7th. The technology company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.20). The firm had revenue of $444.33 million for the quarter, compared to the consensus estimate of $459.43 million. Evolent Health had a negative net margin of 5.94% and a positive return on equity of 1.83%. The business’s revenue was down 31.3% compared to the same quarter last year. During the same period last year, the company posted $0.30 EPS. Evolent Health has set its Q3 2025 guidance at EPS. As a group, analysts predict that Evolent Health, Inc will post 0.08 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on EVH. Canaccord Genuity Group reaffirmed a “buy” rating and set a $16.00 target price on shares of Evolent Health in a research note on Tuesday, September 9th. BTIG Research reaffirmed a “buy” rating and set a $20.00 target price on shares of Evolent Health in a research note on Tuesday, September 9th. Piper Sandler boosted their target price on shares of Evolent Health from $16.00 to $18.00 and gave the stock an “overweight” rating in a research note on Thursday, August 28th. Truist Financial boosted their target price on shares of Evolent Health from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday, July 17th. Finally, JMP Securities reissued a “market outperform” rating and issued a $13.00 price objective on shares of Evolent Health in a research note on Friday, June 20th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $17.43.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.